Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies granted time-based RSUs and stock options as Nasdaq-compliant inducement awards to five new hires under its 2023 Inducement Plan.

Rhea-AI Summary

Taysha Gene Therapies (TSHA) granted equity awards to five new employees on September 1, 2026 under its 2023 Inducement Plan. The awards comprise restricted stock units (RSUs) for 314,000 shares of common stock and stock options for 92,400 shares, granted as employment inducements under Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments starting on the first anniversary of the vesting commencement date, subject to continued service. The stock options have a $5.70 exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on ongoing employment.

Argus Sep 4 session 1 alert

+0.54% close to close 1.6x rel. volume Open Argus

Details

News Market Reaction – TSHA

$1.78B Mkt Cap at Peak Alert

On Sep 4, the day this news came out, TSHA closed 0.54% above the previous close. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 4 session.

Key Figures

Employees receiving grants: 5 employees RSU shares: 314,000 shares Option shares: 92,400 shares +5 more

Employees receiving grants

5 employees

September 1, 2026 inducement grant

RSU shares

314,000 shares

Restricted stock units granted upon employment

Option shares

92,400 shares

Stock option granted upon employment

Nasdaq listing rule

5635(c)(4)

Inducement grant exemption

Option exercise price

$5.70

Equal to the closing price on the grant date

Option term

10 years

Stock option term

Initial option vesting

25%

Vests on the first anniversary

Remaining option vesting

75%

Vests in equal monthly installments over 36 months

Historical Context

5 past events · Latest: Aug 11

5 events

1. Aug 11

   Second-quarter earnings

   24h Move

   -4.0%

   Revenue fell to zero while expenses and net loss increased year over year.

2. Aug 04

   Earnings scheduling notice

   24h Move

   +4.2%

   The company scheduled its second-quarter results and corporate update conference call.

3. Aug 03

   Manufacturing partnership

   24h Move

   -1.4%

   Catalent partnership expansion added future commercial manufacturing support for TSHA-102.

4. Jun 25

   Clinical program presentations

   24h Move

   +2.1%

   The company announced clinical and preclinical TSHA-102 updates for a Rett meeting.

5. Jun 24

   Public offering

   24h Move

   -10.5%

   Taysha priced common shares and pre-funded warrants to raise about $200 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, inducement plan, nasdaq listing rule 5635(c)(4), adeno-associated virus, +1 more

5 terms

restricted stock units financial

"granted five new employees restricted stock units (RSUs) representing 314,000 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement plan financial

"granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

adeno-associated virus medical

"advancing adeno-associated virus (AAV)-based gene therapies"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

monogenic diseases medical

"gene therapies for severe monogenic diseases of the central nervous system"

A monogenic disease is a medical condition caused by a harmful change in a single gene, where that single faulty instruction is enough to produce symptoms. For investors, these diseases matter because their clear genetic cause can make it easier for drug developers to design targeted therapies, diagnostics, or gene therapies, creating distinct clinical pathways, regulatory considerations, and potentially more predictable commercial opportunities—like fixing one broken line of code in a program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $5.70 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Vice President, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
media@tayshagtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Taysha Gene Therapies (TSHA) grant on September 1, 2026?

Taysha Gene Therapies granted five new employees 314,000 RSUs and a stock option to purchase 92,400 shares of its common stock on September 1, 2026, as inducement awards tied to their employment.

How do the RSUs granted by Taysha Gene Therapies (TSHA) vest for new employees?

The RSUs granted under Taysha’s 2023 Inducement Plan vest in four equal annual installments, beginning on the first anniversary of the vesting commencement date, subject to each employee’s continued service with the company.

What is the exercise price and term of the new Taysha Gene Therapies (TSHA) stock options?

The newly granted stock option has an exercise price of $5.70 per share, equal to the closing price on the grant date, and carries a 10-year term from the date of grant.

What is the vesting schedule for the new Taysha Gene Therapies (TSHA) stock options?

The stock option vests over four years: 25% vests on the first anniversary of the vesting commencement date, and the remaining 75% vests in equal monthly installments over the following 36 months, subject to continued service.

Under which plan and Nasdaq rule were the new TSHA inducement grants made?

The RSUs and stock option were granted under the Taysha Gene Therapies 2023 Inducement Plan as inducement awards material to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).